Deutsche Bank’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.5M | Buy |
174,459
+45,217
| +35% | +$3.3M | ﹤0.01% | 927 |
|
|
2026
Q1 | $6.52M | Buy |
129,242
+7,301
| +6% | +$275K | ﹤0.01% | 1191 |
|
|
2025
Q4 | $3.99M | Buy |
121,941
+83,398
| +216% | +$2.18M | ﹤0.01% | 1413 |
|
|
2025
Q3 | $646K | Buy |
38,543
+4,605
| +14% | +$75.1K | ﹤0.01% | 2421 |
|
|
2025
Q2 | $508K | Buy |
33,938
+5,455
| +19% | +$80.7K | ﹤0.01% | 2453 |
|
|
2025
Q1 | $460K | Sell |
28,483
-2,935
| -9% | -$61.1K | ﹤0.01% | 2535 |
|
|
2024
Q4 | $731K | Buy |
31,418
+9,910
| +46% | +$291K | ﹤0.01% | 2414 |
|
|
2024
Q3 | $633K | Buy |
21,508
+5,263
| +32% | +$147K | ﹤0.01% | 2334 |
|
|
2024
Q2 | $382K | Buy |
16,245
+15,947
| +5,351% | +$538K | ﹤0.01% | 2469 |
|
|
2024
Q1 | $11.3K | Buy |
+298
| New | +$8.63K | ﹤0.01% | 3525 |
|
|
2022
Q2 | – | Sell |
-20,605
| Closed | -$1.19M | – | 4316 |
|
|
2022
Q1 | $1.19M | Buy |
20,605
+19,624
| +2,000% | +$1.65M | ﹤0.01% | 2243 |
|
|
2021
Q4 | $117K | Buy |
981
+51
| +5% | +$8.05K | ﹤0.01% | 3640 |
|
|
2021
Q3 | $185K | Sell |
930
-30
| -3% | -$5.25K | ﹤0.01% | 3604 |
|
|
2021
Q2 | $167K | Sell |
960
-269
| -22% | -$48.9K | ﹤0.01% | 3888 |
|
|
2021
Q1 | $243K | Sell |
1,229
-110
| -8% | -$21.1K | ﹤0.01% | 3532 |
|
|
2020
Q4 | $263K | Sell |
1,339
-1,283
| -49% | -$266K | ﹤0.01% | 3317 |
|
|
2020
Q3 | $465K | Buy |
2,622
+81
| +3% | +$15K | ﹤0.01% | 2677 |
|
|
2020
Q2 | $588K | Buy |
2,541
+501
| +25% | +$95.4K | ﹤0.01% | 2539 |
|
|
2020
Q1 | $238K | Sell |
2,040
-511
| -20% | -$86.9K | ﹤0.01% | 2860 |
|
|
2019
Q4 | $486K | Buy |
2,551
+2,269
| +805% | +$445K | ﹤0.01% | 2735 |
|
|
2019
Q3 | $53K | Sell |
282
-396
| -58% | -$77.1K | ﹤0.01% | 3901 |
|
|
2019
Q2 | $115K | Sell |
678
-236
| -26% | -$40.8K | ﹤0.01% | 4136 |
|
|
2019
Q1 | $183K | Buy |
914
+146
| +19% | +$30.4K | ﹤0.01% | 4055 |
|
|
2018
Q4 | $143K | Sell |
768
-721
| -48% | -$153K | ﹤0.01% | 4047 |
|
|
2018
Q3 | $356K | Sell |
1,489
-5,931
| -80% | -$1.39M | ﹤0.01% | 3960 |
|
|
2018
Q2 | $1.96M | Buy |
+7,420
| New | +$1.83M | ﹤0.01% | 2974 |
|
|
2017
Q3 | – | Sell |
-20
| Closed | -$1K | – | 5072 |
|
|
2017
Q2 | $1K | Sell |
20
-178
| -90% | -$24.6K | ﹤0.01% | 4874 |
|
|
2017
Q1 | $36K | Buy |
+198
| New | +$28K | ﹤0.01% | 4328 |
|
|
2016
Q3 | – | Sell |
-37
| Closed | -$4K | – | 5185 |
|
|
2016
Q2 | $4K | Buy |
+37
| New | +$7.09K | ﹤0.01% | 5032 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Deutsche Bank's SYRE Position: Q2 2026 in Review
Deutsche Bank increased its Spyre Therapeutics (SYRE) stake by 35% in Q2 2026, buying an estimated $3.3M and bringing the position to 174,459 shares worth $15.5M. The position accounts for ﹤0.01% of the portfolio, ranked #927.
Deutsche Bank first reported a position in SYRE in Q2 2016 and has held it in 29 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Deutsche Bank held 174,459 shares of Spyre Therapeutics worth $15.5M as of Q2 2026.
- Deutsche Bank bought 45,217 Spyre Therapeutics shares in Q2 2026, an estimated $3.3M.
- Spyre Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #927 holding.
- Deutsche Bank first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 29 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.